Target
PD-1/PD-L1
4 abstracts
Abstract
Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin + pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up.Org: Cleveland Clinic Lerner College of Medicine, University of California San Diego, Yale Cancer Center, University of California, San Francisco Medical Center, Stanford University School of Medicine, Division of Oncology,
Abstract
Association of ephrinB2 (B2) expression on overall survival (OS) and resistance to PD1/L1 inhibitors (inh) in metastatic urothelial carcinoma (mUC).Org: Vasgene Therapeutics, Inc, Newark, NJ, Orlando, FL,
Abstract
Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-VEGFR targeted therapy: A Phase 2 Trial of Regorafenib combined with avelumab.Org: ImmuSmol,
Abstract
Delivery of precision oncology in advanced lung cancer: Gaps, barriers, and potential solutions.Org: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, Chapel Hill, NC, NC Translational and Clinical Sciences Institute, The University of North Carolina at Chapel Hill, University of North Carolina School of Public Health,